Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_361c6223f33de77431dc880348294a7c |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-207 |
filingDate |
2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434d98a1ceff3eab095884b141893a7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575ae645b209afd6ef29f8d5166d1981 |
publicationDate |
2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018030082-A1 |
titleOfInvention |
Beta-d-2'-deoxy-2'-alpha-fluoro-2'beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
abstract |
A compound of the structure: n n n n n n n n n n or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein. |
priorityDate |
2015-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |